Bayer Reports Positive Outcomes for Sarcoma Patients with Regorafenib eMaxHealth Bayer AG has announces that the results of two separate trials show positive outcomes in patients with two forms of cancer, metastatic bowel cancer and a rare form of tumor known as gastrointestinal stromal tumors (GISTs), a type of soft-tissue sarcoma. |
Saturday, November 24, 2012
Bayer Reports Positive Outcomes for Sarcoma Patients with Regorafenib - eMaxHealth
ogarawo.wordpress.com
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment